Arrowhead Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARWR Nasdaq 2830 arrowheadpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arrowhead Pharmaceuticals, Inc.

Piper Sandler Highlights Arrowhead Pharmaceuticals, Inc. (ARWR) Pipeline With Upcoming Phase III Hypertriglyceridemia Data - Jan 22nd, 2026 1:20 am
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results - Jan 20th, 2026 2:30 pm
RNAi Obesity Wins And REDEMPLO’s China Nod Could Be A Game Changer For Arrowhead (ARWR) - Jan 20th, 2026 4:07 am
Arrowhead Pharmaceuticals, Inc. (ARWR): A Bull Case Theory - Jan 19th, 2026 3:18 pm
Arrowhead Pharmaceuticals Touts Rudemplo Launch, Obesity RNAi Data and $920M Cash at JPM Conference - Jan 12th, 2026 3:43 pm
Piper Sandler Maintains an Overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR) - Jan 10th, 2026 11:09 pm
Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million? - Jan 10th, 2026 6:27 pm
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approvals And New Obesity Trial Data - Jan 9th, 2026 10:12 am
Arrowhead Pharmaceuticals Prices Offerings of Notes, Common Stock, Pre-Funded Warrants - Jan 8th, 2026 3:57 am
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants - Jan 7th, 2026 9:05 pm
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China - Jan 7th, 2026 5:30 am
ARWR: Encouraging Early Data for Obesity Programs… - Jan 7th, 2026 4:40 am
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock - Jan 6th, 2026 4:14 pm
Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss - Jan 6th, 2026 2:28 pm
Arrowhead Pharmaceuticals Shares Early RNAi Obesity Data, Highlights Visceral Fat Drops and Combo Potential - Jan 6th, 2026 11:18 am
Zepbound Boost Gets a Lift From Arrowhead’s Drug. The Question Is Whether Patients Will Pay. - Jan 6th, 2026 9:26 am
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition - Jan 6th, 2026 5:30 am
Arrowhead Pharmaceuticals (ARWR) Is Down 5.0% After First-in-Class FCS siRNA Approval in Canada - Jan 5th, 2026 11:08 pm
Arrowhead Pharmaceuticals Says Health Canada Issues 'Notice of Compliance' for Redemplo for Triglyceride Disorder - Jan 5th, 2026 7:35 am
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) - Jan 5th, 2026 5:30 am